We’re innovative thought leaders and determined advocates who partner with visionary organizations to change health care.
We’re innovative thought leaders and determined advocates who partner with visionary organizations to change health care.
We’re innovative thought leaders and determined advocates who partner with visionary organizations to change health care.
Impact Health is a mission-driven health policy and strategic consulting firm dedicated to improving health and well-being for all.
OUR SERVICES
Strategic Planning
Integrate mission-aligned policy expertise and political acumen into planning and executing your goals.
Government Contracting
Track record of success supporting states and municipalities in innovating or launching new programs.
Our proprietary method for tracking, aggregating, and analyzing state policy trends.
If you believe that every American deserves to be healthy and well, contact Impact Health Policy Partners to learn how our expertise can help you achieve your goals.
Policy Hub, managed by Impact Health Policy Partners, is the only comprehensive database of Federal health policy developments, cataloged by over 200 healthcare topics and programs. Regulations, reimbursement, grants, ACA implementation, hearing summaries, CRS Reports, pending legislation – you get it all here, with comprehensive, expert analysis.
Agencies Extend Deadline for Public Comment on Updated Guidance for Collaborations Among Competitors; Due May 21
Today, the Federal Trade Commission (FTC) and the Department of Justice’s (DOJ) Antitrust Division announced that they are extending the deadline for public comment on whether to issue updated guidance on collaborations among competitors (press release). The extension is intended to give stakeholders additional time to provide more comprehensive input on modernizing guidance for the business community. The effort builds on… (Eisen, April 17, 2026) <span style="font-size:90%;
Committee Examines Drug Pricing Competition; Bipartisan Focus on Biosimilars and Generics with Divisions Over Pricing Reforms and Trump Administration Efforts
The Senate Health, Education, Labor, and Pensions Committee convened a hearing to examine how increasing competition, particularly from generics and biosimilars, can lower prescription drug prices. Witnesses representing health policy, industry-aligned research, and consumer advocacy perspectives discussed regulatory barriers, market dynamics, and policy reforms needed to improve access to lower-cost medicines while maintaining incentives for innovation. Witnesses, Dr. Brian Miller,… (Colocho, April 17, 2026) #340B, #Affordable Care Act, #Drug Pricing, #Food and Drug Administration, #Generic Drugs, #Pharmacies, #Pharmacy Benefit Managers, #Prescription Drugs, #Transparency